Upland Software, Inc. (NASDAQ:UPLD) tinted gains of +1.67% (+0.52 points) to US$31.72. The volume of 0.19 Million shares climbed down over an trading activity of 254.06 Million shares. EPS ratio determined by looking at last 12 month figures is -0.9. Over the same time span, the stock marked US$33.56 as its best level and the lowest price reached was US$18.52. The corporation has a market cap of US$636.94 Million.
Upland Software, Inc. (NASDAQ:UPLD)’s earnings per share has been growing at a -28.5 percent rate over the past 5 year when average revenue increase was noted as 33.9 percent. The return on equity ratio or ROE stands at -17.2 percent while most common profitability ratio return on investment (ROI) was -6.5 percent. The company’s institutional ownership is monitored at 56.3 percent. The company’s net profit margin has achieved the current level of -15 percent and possesses 65.8 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.86. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Oncobiologics, Inc. (NASDAQ:ONS) is worth US$25.88 Million and has recently risen 1.67% to US$1.01. The latest exchange of 0.11 Million shares is below its average trading activity of 29.1 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$2.3 while the mean 12-month price target for the shares is US$1.5.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0, and a price to sales ratio of 6.02. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 14.9%, it carries an earnings per share ratio of -1.57.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.